論文

査読有り
2016年1月

Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients

JOURNAL OF INFECTION AND CHEMOTHERAPY
  • Karin Kato
  • ,
  • Miki Nagao
  • ,
  • Masaki Yamamoto
  • ,
  • Yasufumi Matsumura
  • ,
  • Shunji Takakura
  • ,
  • Kazuhiko Fukuda
  • ,
  • Satoshi Ichiyama

22
1-2
開始ページ
27
終了ページ
31
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.jiac.2015.09.008
出版者・発行元
ELSEVIER SCIENCE BV

Voriconazole is used for treating or preventing invasive aspergillosis and other invasive fungal infections. To minimize adverse reactions and to maximize treatment effects, therapeutic drug monitoring should be performed. However, it is challenging to optimize daily voriconazole dosing because limited data have been published so far on pediatric patients.
We retrospectively analyzed voriconazole concentrations in patients aged 0-18 years. In addition, a literature review was conducted. In our study cohort, younger age and oral administration were significantly associated with lower plasma voriconazole concentrations (P < 0.01). An unfavorable outcome was associated with low concentrations of voriconazole (P = 0.01). Reports of voriconazole administration in pediatric patients show that higher doses are required in younger children and in patients receiving oral administration. Hence, the current data suggest that we should escalate both initial and maintenance doses of voriconazole in pediatric patients, particularly in patients of younger age receiving an oral administration of voriconazole. (C) 2015, Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Web of Science ® 被引用回数 : 4

リンク情報
DOI
https://doi.org/10.1016/j.jiac.2015.09.008
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/26538245
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000371369400005&DestApp=WOS_CPL

エクスポート
BibTeX RIS